Literature DB >> 18286696

Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B.

Jing You1, Hutcha Sriplung, Alan Geater, Virasakdi Chongsuvivatwong, Lin Zhuang, Hong-Ying Chen, Lan Yu, Bao-Zhang Tang, Jun-Hua Huang.   

Abstract

AIM: To investigate peripheral T-lymphocyte sub-population profile and its correlation with hepatitis B virus (HBV) replication in patients with chronic hepatitis B (CHB).
METHODS: Distribution of T-lymphocyte subpopulations in peripheral blood was measured by flow cytometry in 206 CHB patients. HBV markers were detected with ELISA. Serum HBV DNA load was assessed with quantitative real-time polymerase chain reaction (PCR). The relationship between HBV replication and variation in peripheral T-cell subsets was analyzed.
RESULTS: CHB patients had significantly decreased CD3+ and CD4+ cells and CD4+/CD8+ ratio, and increased CD8+ cells compared with uninfected controls (55.44 +/- 12.39 vs 71.07 +/- 4.76, 30.92 +/- 7.48 vs 38.94 +/- 3.39, 1.01 +/- 0.49 vs 1.67 +/- 0.33, and 34.39 +/- 9.22 vs 24.02 +/- 4.35; P < 0.001, respectively). Univariate analysis showed a similar pattern of these parameters was significantly associated with high viral load, presence of serum hepatitis B e antigen (HBeAg) expression, liver disease severity, history of maternal HBV infection, and young age at HBV infection, all with P < 0.01. There was a significant linear relationship between viral load and these parameters of T-lymphocyte subpopulations (linear trend test P < 0.001). There was a negative correlation between the levels of CD3+ and CD4+ cells and CD4+/CD8+ ratio and serum level of viral load in CHB patients (r = -0.68, -0.65 and -0.75, all P < 0.0001), and a positive correlation between CD8+ cells and viral load (r = 0.70, P < 0.0001). There was a significant decreasing trend in CD3+ and CD4+ cells and CD4+/CD8+ ratio with increasing severity of hepatocyte damage and decreasing age at HBV infection (linear trend test P < 0.01). In multiple regression (after adjustment for age at HBV infection, maternal HBV infection status and hepatocyte damage severity) log copies of HBV DNA maintained a highly significant predictive coefficient on T-lymphocyte subpopulations, and was the strongest predictor of variation in CD3+, CD4+, CD8+ cells and CD4+/CD8+ ratio. However, the effect of HBeAg was not significant.
CONCLUSION: T-lymphocyte failure was significantly associated with viral replication level. The substantial linear dose-response relationship and strong independent predictive effect of viral load on T-lymphocyte subpopulations suggests the possibility of a causal relationship between them, and indicates the importance of viral load in the pathogenesis of T cell hyporesponsiveness in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286696      PMCID: PMC2689417          DOI: 10.3748/wjg.14.1112

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  A new hypothesis of pathogenetic mechanism of viral hepatitis B and C.

Authors:  D X Liu
Journal:  Med Hypotheses       Date:  2001-03       Impact factor: 1.538

2.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 3.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 4.  Recent advances in hepatitis B virus research: a German point of view.

Authors:  Dieter Glebe
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

5.  [The guidelines of prevention and treatment for chronic hepatitis B].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-12

6.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

Authors:  Jeroen N Stoop; Renate G van der Molen; Carla C Baan; Luc J W van der Laan; Ernst J Kuipers; Johannes G Kusters; Harry L A Janssen
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

7.  Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations.

Authors:  S K Sarin; V Thakur; R C Guptan; S Saigal; V Malhotra; S P Thyagarajan; B C Das
Journal:  J Gastroenterol Hepatol       Date:  2001-06       Impact factor: 4.029

Review 8.  The immune response during hepatitis B virus infection.

Authors:  Antonio Bertoletti; Adam J Gehring
Journal:  J Gen Virol       Date:  2006-06       Impact factor: 3.891

9.  Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice.

Authors:  M Chen; M Sällberg; S N Thung; J Hughes; J Jones; D R Milich
Journal:  Antiviral Res       Date:  2001-11       Impact factor: 5.970

10.  Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.

Authors:  George K K Lau; Deepak Suri; Raymond Liang; Eirini I Rigopoulou; Mark G Thomas; Ivana Mullerova; Amin Nanji; Siu-Tsan Yuen; Roger Williams; Nikolai V Naoumov
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

View more
  11 in total

Review 1.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

Review 2.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.

Authors:  Yi-Fu He; Juan Jin; Wei Wei; Yan Chang; Bing Hu; Chu-Shu Ji; Wei-Dong Jia; Xiao-Qiu Wang; Ke Chen; Jian Chen
Journal:  Can J Gastroenterol       Date:  2010-07       Impact factor: 3.522

4.  Chronic hepatitis B: the demise of the 'inactive carrier' phase.

Authors:  Apostolos Koffas; Manoj Kumar; Upkar S Gill; Ankur Jindal; Patrick T F Kennedy; S K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

5.  Impaired antigen processing and presentation machinery is associated with immunotolerant state in chronic hepatitis B virus infection.

Authors:  Sukriti Sukriti; Nirupma Trehan Pati; Sujoy Bose; Syed S Hissar; Shiv Kumar Sarin
Journal:  J Clin Immunol       Date:  2010-03-19       Impact factor: 8.317

6.  Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Authors:  Hui Zhang; Jianchun Xian; Yang Li; Li Xiao; Lu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

7.  Public awareness of three major infectious diseases in rural Zhejiang province, China: a cross-sectional study.

Authors:  He Liu; Mei Li; Mingjuan Jin; Fangyuan Jing; Hui Wang; Kun Chen
Journal:  BMC Infect Dis       Date:  2013-04-29       Impact factor: 3.090

8.  Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients.

Authors:  Christian A Engell; Vinh Philip Pham; Robert S Holzman; Judith A Aberg
Journal:  ISRN Gastroenterol       Date:  2011-06-13

Review 9.  Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.

Authors:  Hyosun Cho; Hyojeung Kang; Hwan Hee Lee; Chang Wook Kim
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

10.  Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients.

Authors:  Y Shi; Y Lan; F Cao; Y Teng; L Li; F Wang; J Li; J Zhou; Y Li
Journal:  J Viral Hepat       Date:  2014-03-12       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.